JMIR public health and surveillance · 2025
Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smith-Roberge Julien, Forouzannia Farinaz, Hamadeh Abdullah, Feng Zeny, Popovic Nashira, Wong William W L
Аннотация
BACKGROUND: Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the global strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades.
OBJECTIVE: This study develops a framework to estimate the prevalence of CHB and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021.
METHODS: We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of CHB, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada.
RESULTS: We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI 0.443%-0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI 50.9%-58.9%).
CONCLUSIONS: The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data.
OBJECTIVE: This study develops a framework to estimate the prevalence of CHB and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021.
METHODS: We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of CHB, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada.
RESULTS: We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI 0.443%-0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI 50.9%-58.9%).
CONCLUSIONS: The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data.